ArticleHealth care science2026
A Pharmacogenomics-Guided Antihypertensive Strategy for Blood Pressure Reduction in Rural China: A Cluster-Randomized Controlled Trial.
Article in Health care science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although pharmacogenomics can effectively guide antihypertensive treatment, relevant evidence from low‑resource primary care settings is lacking. The aim of this study is to evaluate a pharmacogenomic‑guided antihypertensive strategy in real‑world, low‑resource primary care settings. Methods: We randomly assigned 94 villages (in 1:1:1 ratio, with stratification by villages) to receive a multifaceted intervention that included follow-up, health education, and medication adjustment guided by pharmacogenomics (treatment) or physician's experience (control), or routine care (observation) over 4 weeks. The primary outcome was the proportion of patients with controlled blood pressure after 4 weeks of treatment. Generalized linear, linear mixed-effect regression, and sensitivity analysis were conducted to assess the difference among groups. The intracluster correlation coefficient was calculated to assess the heterogeneity with cluster. Results: This study included 1031 hypertensive patients from 90 villages of Dajie and Jiuzhi towns in Daming County from May 10 to December 31, 2022. Overall, 79 loci on 39 antihypertensive-related genes were tested for patients in the treatment group. After 4 weeks of treatment, 371 of 377 (98.4%) patients in the treatment group, 256 of 345 (74.2%) patients in the control group, and 232 of 309 (75.1%) patients in the observation group had their blood pressure under control. The between-group net differences were 24.2% (95% confidence interval [CI]: 19.4%-29.0%) and 23.3% (95% CI: 18.3%-28.3%) for the treatment versus control groups and treatment versus observation groups, respectively. After 4 weeks of treatment, the proportion of patients with overall incident adverse events was no different among the three groups (all Conclusions: A pharmacogenomic-guided antihypertensive strategy can significantly enhance blood pressure control while maintaining a similar safety level compared to an experience-guided antihypertensive strategy in low-resource, primary care settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.